Sun Pharmaceutical Industries Limited (SUNPHARMA) Price & Analysis

Compare

10 Followers

SUNPHARMA Stock Chart & Stats

₹1730.15

-₹15.65(-0.84%)

At close: Jan 08 4:00 PM EST

₹1730.15

-₹15.65(-0.84%)

Day’s Range― - ―

52-Week Range₹1,547.25 - ₹1,850.95

Previous CloseN/A

Volume1.30M

Average Volume (3M)102.58K

Market Cap

₹4.14T

Enterprise Value₹4.07T

Total Cash (Recent Filing)₹261.23B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)37.9

Beta0.79

Next Earnings

May 21, 2026

EPS Estimate

10.69

Next Dividend Ex-DateN/A

Dividend Yield0.91%

Share Statistics

EPS (TTM)14.70

Shares Outstanding2,399,278,300

10 Day Avg. Volume56,056

30 Day Avg. Volume102,581

Financial Highlights & Ratios

PEG Ratio2.61

Price to Book (P/B)5.64

Price to Sales (P/S)7.74

P/FCF Ratio34.08

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,916.33

Price Target Upside10.76% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetA very low debt-to-equity ratio provides durable financial flexibility to fund R&D, capital spending, acquisitions, or weather pricing cycles without stressing liquidity. This structural strength reduces refinancing risk and supports multi-quarter investment in specialty and complex portfolios.

Robust Cash GenerationSolid free cash flow growth and high conversion of earnings into cash enable self-funding of capacity expansion, pipeline development, and shareholder returns. Durable cash generation lowers reliance on external capital and supports medium-term execution of strategy in regulated markets.

Improving Profitability And MarginsSustained margin expansion alongside revenue growth implies structural cost advantages, pricing power in branded/specialty segments, and operational efficiency. Higher margins underpin resilient cash flows and provide resources for reinvesting in higher‑value specialty drugs over several quarters.

Bears Say

Negative EPS GrowthDeclining EPS despite revenue gains points to margin dilution, higher costs, or non-operating impacts that depress per‑share earnings. Persisting EPS weakness can limit per-share returns, reduce flexibility for buybacks/dividends, and signal operational or capital allocation issues over the medium term.

Exposure To Price-Driven Generics MarketsLarge exposure to commoditized generics—where competition is primarily on price and supply—constitutes a structural margin risk. Sustained price erosion in developed markets can compress returns unless offset by scale, cost leadership, or growth in differentiated specialty products.

Revenue Visibility Tied To Approval TimelinesReliance on regulatory approvals and launch timing creates durable execution risk: delays or setbacks in key regulated markets can defer expected revenue and disrupt multi-quarter growth plans. Consistent pipeline delivery is critical to sustain medium-term revenue momentum.

Sun Pharmaceutical Industries Limited News

Sun Pharma’s GL0034 Diabetes Trial: Early-Stage Data Catalyst in a Crowded Metabolic Market

Sun Pharmaceutical Industries Limited ($IN:SUNPHARMA) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Ltd. is...

11d ago

Sun Pharma Advances GL0034 Diabetes Program With Kidney Function Study, Supporting Long-Term Pipeline Story

Sun Pharmaceutical Industries Limited ($IN:SUNPHARMA) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries is preparing...

18d ago

Sun Pharma Publishes Q3 FY26 Unaudited Results Notice in Newspapers

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) just unveiled an update. Sun Pharmaceutical Industries Limited has notified the...

22d ago

Sun Pharma’s INSPIRE 1 Psoriatic Arthritis Trial Nears Key Data Milestone

Sun Pharmaceutical Industries Limited ($IN:SUNPHARMA) announced an update on their ongoing clinical study. Study Overview: Sun Pharmaceutical Industries...

1M ago

Sun Pharma Rolls Out UNLOXCYT in U.S. for Advanced Skin Cancer Patients

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) just unveiled an update. Sun Pharmaceutical Industries has launched UNLOXCYT (cosibelimab-ipdl)...

1M ago

Sun Pharma’s Baska Facility Receives OAI Classification from US FDA

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) has provided an update. Sun Pharmaceutical Industries Limited announced that the...

2M ago

Sun Pharma to Invest INR 3,000 Crores in New Manufacturing Facility

Sun Pharmaceutical Industries Limited ( ($IN:SUNPHARMA) ) just unveiled an announcement. Sun Pharmaceutical Industries Limited announced that its...

3M ago

Sun Pharma’s New Study on Actinic Keratosis Treatment: What Investors Need to Know

Sun Pharmaceutical Industries Limited (($IN:SUNPHARMA)) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Limited is...

4M ago

Sun Pharma’s New Clinical Trial: A Potential Game-Changer for Actinic Keratosis Treatment

Sun Pharmaceutical Industries Limited (($IN:SUNPHARMA)) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Limited is...

4M ago

Sun Pharma’s Alopecia Areata Study: A Potential Game Changer?

Sun Pharmaceutical Industries Limited (($IN:SUNPHARMA)) announced an update on their ongoing clinical study. Sun Pharmaceutical Industries Limited is...

4M ago

SUNPHARMA FAQ

What was Sun Pharmaceutical Industries Limited’s price range in the past 12 months?

Sun Pharmaceutical Industries Limited lowest stock price was ₹1547.25 and its highest was ₹1850.95 in the past 12 months.

What is Sun Pharmaceutical Industries Limited’s market cap?

Sun Pharmaceutical Industries Limited’s market cap is ₹4.14T.

When is Sun Pharmaceutical Industries Limited’s upcoming earnings report date?

Sun Pharmaceutical Industries Limited’s upcoming earnings report date is May 21, 2026 which is in 87 days.

How were Sun Pharmaceutical Industries Limited’s earnings last quarter?

Sun Pharmaceutical Industries Limited released its earnings results on Jan 31, 2026. The company reported ₹14.7 earnings per share for the quarter, beating the consensus estimate of ₹12.909 by ₹1.791.

Is Sun Pharmaceutical Industries Limited overvalued?

According to Wall Street analysts Sun Pharmaceutical Industries Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sun Pharmaceutical Industries Limited pay dividends?

Sun Pharmaceutical Industries Limited pays a Semiannually dividend of ₹5.5 which represents an annual dividend yield of 0.91%. See more information on Sun Pharmaceutical Industries Limited dividends here

What is Sun Pharmaceutical Industries Limited’s EPS estimate?

Sun Pharmaceutical Industries Limited’s EPS estimate is 10.69.

How many shares outstanding does Sun Pharmaceutical Industries Limited have?

Sun Pharmaceutical Industries Limited has 2,399,278,300 shares outstanding.

What happened to Sun Pharmaceutical Industries Limited’s price movement after its last earnings report?

Sun Pharmaceutical Industries Limited reported an EPS of ₹14.7 in its last earnings report, beating expectations of ₹12.909. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Sun Pharmaceutical Industries Limited?

Currently, no hedge funds are holding shares in IN:SUNPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.

Sun Pharmaceutical Industries Limited (SUNPHARMA) Earnings & Revenues

Historic Earnings Reports

SUNPHARMA Stock 12 Month Forecast

Average Price Target

₹1,916.33

▲(10.76% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1552":"₹1,552","1941":"₹1,941","1649.25":"₹1,649.3","1746.5":"₹1,746.5","1843.75":"₹1,843.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1940,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.94K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1916.333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.92K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1899,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.90K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1552,1649.25,1746.5,1843.75,1941],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1618.384,1643.1236923076924,1667.8633846153846,1692.603076923077,1717.3427692307691,1742.0824615384615,1766.822153846154,1791.561846153846,1816.3015384615385,1841.0412307692309,1865.780923076923,1890.5206153846154,1915.2603076923076,{"y":1940,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1618.384,1641.3031794871795,1664.222358974359,1687.1415384615384,1710.0607179487179,1732.9798974358973,1755.8990769230768,1778.8182564102563,1801.7374358974357,1824.6566153846152,1847.5757948717946,1870.494974358974,1893.4141538461536,{"y":1916.333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1618.384,1639.9698461538462,1661.5556923076924,1683.1415384615384,1704.7273846153846,1726.3132307692308,1747.899076923077,1769.484923076923,1791.0707692307692,1812.6566153846154,1834.2424615384616,1855.8283076923076,1877.4141538461538,{"y":1899,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1779.911,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1860.234,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1715.829,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1578.416,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1680.464,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1812.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1651.003,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1618.533,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1553.257,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1625.588,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1678.941,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1709.294,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1618.384,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >